Results: Currently, clinical follow-up was available in 628 patients and angiographic follow-up in 526 patients (608 lesions). The primary endpoints were not statistically different between the 6-and 12-month DAPT groups, including MACE (4.6 vs. 3.4%; p ¼0.49) and stent thrombosis (0.0 vs. 0.3%; p ¼ 0.71), and MACE (3.4 vs. 4.6%; p ¼0.49) and stent thrombosis (0.3 vs. 0.0%; p ¼ 0.71), according as type of stents (BES vs. ZES, respectively). The secondary endpoints also were not significantly different between the 6-and 12-month DAPT groups, including target lesion failure (2.0 vs. 1.6%; p ¼ 0.53), in-segment LL (mm) at 12 months (0.09AE0.37 vs. 0.05AE0.39, p ¼0.61). Similar results were shown between stents type. And NIH CSA (mm2) at 6month between BES and ZES were 0.38AE0.28, 0.45AE0.32, respectively (p¼0.41). Conclusions: Six-month DAPT did not increase the risk of MACE, stent thrombosis, target lesion failure, and LL at 12 months after implantation of drug-eluting stents compared with 12-month DAPT. The 2nd generation DES including BES and ZES are comparably efficacious. Our results need to be confirmed in larger trials and further follow up data.
Background: On-treatment platelet reactivity to clopidogrel is variable and in part genetic dependent. In African American (AA) patients, the relation between ontreatment platelet reactivity to clopidogrel and the factors that influence this interaction are unknown. The present study aims to evaluate on-treatment platelet reactivity to clopidogrel in AA patients and its interaction to race and CYP2C19*2 loss of function mutation. Methods: The study cohort included 289 consecutive patients presenting for percutaneous coronary intervention (PCI) who were entered into a prospective, observational registry. High on-treatment platelet reactivity (HTPR) was defined as P2Y12 reaction units (PRU) !208 with VerifyNow P2Y12 assay and >50% by vasodilatorstimulated phosphoprotein phosphorylation assay platelet reactivity index (VASP PRI) measured 6-24 hours post-procedure. CYP2C19*2 (rs4244285) genotype was analyzed by real-time polymerase chain reaction. Results: The prevalence of HTPR by both PRU (56% vs. 35%, p¼0.003) and VASP PRI (67% vs. 45%, p¼0.002) is more common in AA compared to Caucasians, respectively. AA patients had higher on-treatment, mean PRU (207AE110 vs. 160AE102, p¼0.002) and VASP PRI (49AE26 vs. 38AE26, p¼0.004). AA also had a higher prevalence of CYP2C19*2 allele carrier status compared to Caucasians (43% vs. 29%, p¼0.04). AA race (p¼0.008) and CYP2C19*2 allele status (p¼0.02) independently had significant effects on PRU and VASP. Multivariable logistic regression analysis has shown that both CYP2C19*2 allele carrier status and AA race were independent correlates of HTPR for PRU !208.
Conclusions: AA patients undergoing PCI not only have a higher prevalence of HTPR to clopidogrel but also have higher CYP2C19*2 allele carrier status compared to Caucasians. Careful selection of antiplatelet agents should be considered in an AA population at higher risk for ischemic complications.
TCT-10
Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Background: Comparative effectiveness studies may seek to enroll geographically diverse populations to enhance generalizability. We compared enrollment, randomization, drug and device utilization between US and non US patients across a large international trial. Methods: The Dual Antiplatelet Therapy (DAPT) Study is a double-blind randomized trial designed to compare durations of DAPT after PCI with stents with respect to clinical events. Patients were enrolled between August 2009 and July 2011. At 12 months, eligible patients were randomized to receive placebo+aspirin or thienopyridine+aspirin through study endpoint (30 months). We compared patient and procedure characteristics, patterns of stent and medication choice, compliance with antiplatelet therapy, and randomization rates, between patients enrolled in the US and other countries. . Non-US patients were more likely to be male, current smokers, present with acute coronary syndrome, receive bare metal vs drug-eluting stents, clopidogrel vs prasugrel, and aspirin doses 100 mg daily (each p<0.001). At 12m, non-US patients were more likely to be DAPT compliant (94.7 vs 89.2%, p<0.001). Non-US patients were more likely to be randomized (65% vs 43%, p <0.001), even after adjusting for baseline characteristics (OR¼ 2.27; p<0.001). Conclusions: Within the DAPT Study, non-US patients were more likely to be compliant with study procedures, independent of patient characteristics. Regional variation in patient characteristics, compliance, and practice patterns observed in broadly inclusive clinical trials allows for the evaluation of interactions between these factors and treatment effectiveness.
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